Dr Adam Walker

Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response

A Walker, M Mohebbi, M Maes, M Berk, K Walder, C Bortolasci, Z Liu, C Ng, M Ashton, L Berk, A Singh, G Malhi, O Dean

(2023), Vol. 27, Brain, Behavior, and Immunity - Health, C1

The Australian Genetics of Depression Study: New Risk Loci and Dissecting Heterogeneity Between Subtypes

B Mitchell, A Campos, D Whiteman, C Olsen, S Gordon, A Walker, O Dean, M Berk, I Hickie, S Medland, N Wray, N Martin, E Byrne

(2022), Vol. 92, pp. 227-235, Biological Psychiatry, United States, C1

The role of metformin as a treatment for neuropsychiatric illness

S Dodd, L Sominsky, D Siskind, C Bortolasci, A Carvalho, M Maes, A Walker, K Walder, A Yung, L Williams, H Myles, T Watson, M Berk

(2022), Vol. 64, pp. 32-43, European Neuropsychopharmacology, Netherlands, C1

Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials

R Zazula, M Husain, M Mohebbi, A Walker, I Chaudhry, A Khoso, M Ashton, B Agustini, N Husain, J Deakin, A Young, M Berk, B Kanchanatawan, C Ng, M Maes, L Berk, A Singh, G Malhi, O Dean

(2021), Vol. 55, pp. 784-798, Australian and New Zealand Journal of Psychiatry, England, C1

The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies

W Marx, A McGuinness, T Rocks, A Ruusunen, J Cleminson, A Walker, S Gomes-da-Costa, M Lane, M Sanches, A Diaz, P Tseng, P Lin, M Berk, G Clarke, A O’Neil, F Jacka, B Stubbs, A Carvalho, J Quevedo, J Soares, B Fernandes

(2021), Vol. 26, pp. 4158-4178, Molecular Psychiatry, England, C1

Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Péricarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrôlé par placebo

A Turner, A Baker, O Dean, A Walker, S Dodd, S Cotton, J Scott, B Kavanagh, M Ashton, E Brown, J McGrath, M Berk

(2021), Vol. 66, pp. 354-366, Canadian Journal of Psychiatry, United States, C1

Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry

G Morris, A Walker, K Walder, M Berk, W Marx, A Carvalho, M Maes, B Puri

(2021), Vol. 58, pp. 2158-2182, Molecular Neurobiology, United States, C1

The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial

W Marx, D Skvarc, M Mohebbi, A Walker, A Meehan, A Turner, A Baker, S Dodd, S Cotton, J Scott, B Kavanagh, M Ashton, E Brown, J McGrath, M Berk, O Dean

(2021), Vol. 12, Frontiers in Psychiatry, Switzerland, C1

Statins: Neurobiological underpinnings and mechanisms in mood disorders

A Walker, Y Kim, I Borissiouk, R Rehder, S Dodd, G Morris, A Nierenberg, M Maes, B Fernandes, O Dean, L Williams, H Eyre, S Kim, S Zoungas, A Carvalho, M Berk

(2021), Vol. 128, pp. 693-708, Neuroscience and Biobehavioral Reviews, Amsterdam, The Netherlands, C1

Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial

C Bortolasci, A Turner, M Mohebbi, Z Liu, M Ashton, L Gray, W Marx, A Walker, G Kowalski, F Jacka, M Berk, O Dean, K Walder

(2021), Vol. 142, pp. 376-383, Journal of Psychiatric Research, England, C1

Exploring interleukin-6, lipopolysaccharide binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression

K Hasebe, M Mohebbi, L Gray, A Walker, C Bortolasci, A Turner, M Berk, K Walder, M Maes, B Kanchanatawan, M Ashton, L Berk, C Ng, G Malhi, A Singh, O Dean

(2021), Vol. 34, Acta Neuropsychiatrica, England, C1

The impact of removal of ovarian hormones on cholinergic muscarinic receptors: Examining prepulse inhibition and receptor binding

S Ch’ng, A Walker, M McCarthy, T Le, N Thomas, A Gibbons, M Udawela, S Kusljic, B Dean, A Gogos

(2020), Vol. 10, Brain Sciences, Switzerland, C1

Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis

C Bortolasci, W Marx, A Walker, K Hasebe, B Kavanagh, M Morris, M Mohebbi, A Turner, L Gray, L Berk, K Walder, M Berk, O Dean

(2020), Vol. 10, pp. e035080-, BMJ open, England, C1

Insulin-stimulated mTOR activation in peripheral blood mononuclear cells associated with early treatment response to lithium augmentation in rodent model of antidepressant-resistance

A Walker, J Price, K Borreggine, S Sutor, A Gogos, J McGillivray, M Frye, S Tye

(2019), Vol. 9, Translational Psychiatry, United States, C1

Statins and inflammation: New therapeutic opportunities in psychiatry

S Kim, H Kang, M Jhon, J Kim, J Lee, A Walker, B Agustini, J Kim, M Berk

(2019), Vol. 10, Frontiers in Psychiatry, Switzerland, C1

The therapeutic potential of mangosteen pericarp as an adjunctive therapy for bipolar disorder and schizophrenia

M Ashton, O Dean, A Walker, C Bortolasci, C Ng, M Hopwood, B Harvey, M Möller, J McGrath, W Marx, A Turner, S Dodd, J Scott, J Khoo, K Walder, J Sarris, M Berk

(2019), Vol. 10, Frontiers in Psychiatry, Switzerland, C1

Protocol and rationale: a 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostanaLinn. (mangosteen) pericarp for schizophrenia

Alyna Turner, John McGrath, Olivia Dean, Seetal Dodd, Andrea Baker, Susan Cotton, James Scott, Bianca Kavanagh, Melanie Ashton, Adam Walker, Ellie Brown, Michael Berk

(2019), Vol. 17, pp. 297-307, Clinical psychopharmacology and neuroscience, Seoul, South Korea, C1

Has the sun set for seasonal affective disorder and HPA axis studies? A systematic review and future prospects

B Agustini, M Bocharova, A Walker, M Berk, A Young, M Juruena

(2019), Vol. 256, pp. 584-593, Journal of affective disorders, Amsterdam, The Netherlands, C1

The compensatory antioxidant response system with a focus on neuroprogressive disorders

G Morris, B Puri, A Walker, M Berk, K Walder, C Bortolasci, W Marx, A Carvalho, M Maes

(2019), Vol. 95, Progress in Neuro-Psychopharmacology and Biological Psychiatry, England, C1

Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders

R Sethi, N Gómez-Coronado, A Walker, O Robertson, B Agustini, M Berk, S Dodd

(2019), Vol. 10, Frontiers in Psychiatry, Switzerland, C1

Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities

G Morris, B Puri, A Walker, M Maes, A Carvalho, K Walder, C Mazza, M Berk

(2019), Vol. 148, Pharmacological Research, Netherlands, C1

Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders

G Morris, B Puri, A Walker, M Maes, A Carvalho, C Bortolasci, K Walder, M Berk

(2019), Vol. 107, pp. 862-882, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder

S Dodd, A Walker, A Brnabic, N Hong, A Burns, M Berk

(2019), Vol. 21, pp. 142-150, Bipolar Disorders, Denmark, C1

Cell death pathways: a novel therapeutic approach for neuroscientists

G Morris, A Walker, M Berk, M Maes, B Puri

(2018), Vol. 55, pp. 5767-5786, Molecular neurobiology, New York, N.Y., C1

Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking

N Gómez-Coronado, A Walker, M Berk, S Dodd

(2018), Vol. 38, pp. 235-258, Pharmacotherapy, United States, C1

Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases

G Morris, M Berk, A Carvalho, M Maes, A Walker, B Puri

(2018), Vol. 341, pp. 154-175, Behavioural brain research, Amsterdam, The Netherlands, C1

Leaky brain in neurological and psychiatric disorders: drivers and consequences

Gerwyn Morris, Brisa Fernandes, Basant Puri, Adam Walker, Andre Carvalho, Michael Berk

(2018), Vol. 52, pp. 924-948, Australian and New Zealand journal of psychiatry, London, Eng., C1

Differential effects of chronic 17β-oestradiol treatment on rat behaviours relevant to depression

A Gogos, M McCarthy, A Walker, M Udawela, A Gibbons, B Dean, S Kusljic

(2018), Vol. 30, Journal of Neuroendocrinology, United States, C1

Nucleus accumbens deep-brain stimulation efficacy in ACTH-pretreated rats: alterations in mitochondrial function relate to antidepressant-like effects

Y Kim, S McGee, J Czeczor, A Walker, R Kale, A Kouzani, K Walder, M Berk, S Tye

(2016), Vol. 6, pp. e842-, Translational psychiatry, United States, C1

Progesterone: the neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions

Jeehae Sun, Adam Walker, Brian Dean, Maarten van den Buuse, Andrea Gogos

(2016), Vol. 74, pp. 126-140, Psychoneuroendocrinology, Amsterdam, The Netherlands, C1

Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance

A Walker, B Foley, S Sutor, J Mc Gillivray, M Frye, S Tye

(2015), Vol. 293, pp. 198-202, Behavioural brain research, Amsterdam, The Netherlands, C1

Stress, inflammation, and cellular vulnerability during early stages of affective disorders: biomarker strategies and opportunities for prevention and intervention

A Walker, Y Kim, J Price, R Kale, J McGillivray, M Berk, S Tye

(2014), Vol. 5, Frontiers in psychiatry, Lausanne, Switzerland, C1-1

Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels

A Walker, S Burnett, K Hasebe, J McGillivray, L Gray, S McGee, K Walder, M Berk, S Tye

(2013), Vol. 242, pp. 76-83, Behavioural brain research, Amsterdam, The Netherlands, C1